UPDATE: Barclays Downgrades Arcturus Therapeutics (ARCT) to Underweight, 'High Risk of Covid-19 Vaccine Failure'
Tweet Send to a Friend
(Updated - June 21, 2021 4:48 AM EDT)
Barclays analyst Gena Wang downgraded Arcturus Therapeutics (NASDAQ: ARCT) from Equalweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst Gena Wang downgraded Arcturus Therapeutics (NASDAQ: ARCT) from Equalweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
